water under-perform expect recent long-
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data jun
rate updat jun
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
water leadership liquid chromatographi mass
spectrometri market give compel inher competit
edg -- compani larg instal base instrument gener
high consum util benefit sticki base
enjoy greater portion sale high margin consum
higher exposur biopharma market close peer
agil addit greater product sophist
liquid chromatographi make product sell
consider higher price point ga chromatographi
water greater exposur biopharma market also
enabl higher growth rel peer need lc/m lead
biolog molecul research character led high
demand product past year
trend expect continu although slower pace
estim biolog custom segment grown nearli
low-double-digit annual pace last decad
repres custom base
water growth under-perform expect recent
anticip exposur china new product innov
remain key growth driver busi believ
weak stem part under-perform
thermal analysi segment tougher year-over-year comp
biopharma busi like modest market share loss
competitor like agil step lc-m product
offer although manag mistim product refresh
cycl view compani biotof mass spectromet
develop launch instanc cater
specif develop qualiti analysi need
biopharma custom help compani regain
foot meanwhil sale china percentag revenu
doubl last decad repres
close total sale despit grow concern tariff
affect chines custom purchas still anticip healthi
demand sophist high-perform product
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
water provid analyt instrument pharmaceut biochem
industri custom water lead liquid chromatographi market
account roughli total revenu remain sale come
thermal analysi instrument instrument consum informat
servic account approxim sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fair valu estim per share valuat
impli enterpris value/ebitda
price/adjust earn multipl approxim time
although anticip recent sale progress
biopharma market slow time still view water
exposur higher growth market new product
launch exposur china long-term posit
mid-single-digit growth rate come year driven
mostli lc-m segment forecast low-single-digit
growth thermo analysi divis
also forecast stabl profit
dont anticip competit
issu materi shift product mix dramat
alter compani margin assumpt result
return invest capit continu rang
estim compani cost
capit
give water medium uncertainti rate thank
rel high barrier entri moder switch cost
mostli stabl product evolut chromatographi
uptak firm new product steadi price
greater-than-expect perform oversea lead
high-single-digit annual growth nearli
margin expans within five year thank
price power oper leverag
optimist assumpt lead fair valu estim
reflect price-to-earnings multipl approxim
bear-cas scenario fair valu estim
oper margin fall roughli basi point
five year scenario assum increas
price pressur market share loss competit
addit overal slowdown biopharma spend
lc/m equip scenario valu busi
believ wide moat thank larg
compani leadership liquid chromatographi mass
drive adopt compani instrument platform
high switch cost help lock custom
long-term replac cycl custom base
scientist util instrument face steep
learn curv sizabl up-front invest util
special highli sensit equip
market scientist often remain loyal supplier ensur
sampl protect standard minim
consum lc/m machin larg
stick product primari lc column due
compani high manufactur qualiti product
innov avoid lose valuabl data risk
third-parti product water sell nearli mani
origin ubondpak lc column late
higher perform standard new instrument often
lead higher consum attach rate water
launch ultraperform liquid chromatographi uplc
column creat demand instrument materi
perform criteria run higher pressur
instrument user therefor stick
compani column uplc wherea substitut higher
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
consult repair present hurdl new entrant
establish reput brand
water industri lead profit return capit
reflect compani wide moat oper margin
return invest capit excess
last decad respect among highest
life scienc diagnost industri
stabl moat trend view compet
rel stabl market think risk disrupt
technolog low lc/m market rel matur
compani innov lc/m equip
consum continu attract custom grow
instal base machin keep switch cost high
hplc categori
water extens exposur biopharma market
enabl instrument consum becom
engrain drug-manufactur process includ
brand gener small molecul drug manufactur
well total biopharma custom segment
compos revenu give
compani near quarter market share categori
estim research use one platform earli
stage drug develop regul requir
instrument drug life-cycle last
year chang manufactur includ
test impur etc would requir approv
regul agil thermo fisher
shimadzu primari competit
instrument reagent market tend
incorpor high level technolog complex
also keep barrier entri somewhat high opinion
addit challeng manufactur reliabl
complex instrument think necessari servic
compon
market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
owat high perform instrument remain
standard high-perform applic especi
pharma regulatori limit preserv
strategi preserv return capit near
top industri manag prefer focus
core area rather pursu acquisit
dilut return
oemerg market benefit increas
market presenc gener drugmak
increas food safeti environment test
chines govern
oth compani face formid competit ms
like thermo fisher agil market
share slip somewhat past year
competitor activ new
owith nearli sale pharma academ
govern custom lack diversif
mani larger peer compani therefor
expos potenti neg market cycl
owat -base manufactur expos
compani foreign exchang risk
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
clean balanc sheet
invest exceed compani debt balanc
last decad end water
carri billion debt billion cash
invest although could take significantli
debt given firm stabl cash flow manag
avoid larg transact instead return
capit sharehold share repurchas
compani current pay dividend
give water medium uncertainti rate thank
rel high barrier entri moder switch cost
mostli stabl product evolut chromatographi
sheet afford compani plenti flexibl water
equip sale increas exposur macroeconom
condit especi among industri custom
compani larg revenu contribut consum
biopharma custom make busi somewhat
insul spend cycl also
reduc relianc pharma custom top
pharma custom account sale
make one third busi
govern research spend fairli
spend among govern academ custom water
also focus busi oper competit
environ despit smaller thermal analysi segment
consid water essenti pure-play lc/m
market competitor larger diversifi
organ establish competitor new entrant
introduc better product develop stronger relationship
custom compani may lose market share well
abil extract price increas moreov
compani compet mani larger rival invest
signific resourc core busi requir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
maintain technolog edg regardless larg
liquid chromatographi mass spectrometri busi
seem larg immun disrupt technolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
board
maintain exemplari stewardship rate
somewhat concern manag product
pipelin competitor like agil seem
gain share thank innov product
regardless think econom moat remain
strong evidenc industri lead profit
return capit also think manag disciplin
capit alloc strategi preserv high return
repres date owner name posit common share held report holder issuer
share
fund
execut turnov last
year envis major strateg shift
busi chri connel former presid
restor therapi group replac
dougla berthiaum ceo oconnel also
replac berthiaum chairman board
sherri buck becam cfo previou financi
execut experi libbey connel
inherit busi profit return capit
nearli highest industri anticip
compani still follow disciplin capit alloc
strategi far manag follow similar footstep
develop effort return capit sharehold
share repurchas
predecessor
focus
share
fund
think execut team fairli align
sharehold interest insid ownership particularli
larg total compens heavili weight toward
long-term incent base rel total sharehold
return short-term incent base revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
follow quarter better-than-expect result
think new product launch lc-m bioaccord
announc week help support growth
biopharma segment critic
water market segment post fourth-quart
result mostli line expect industri
appli segment sale increas constant-curr
basi consist perform throughout
academ govern sale growth slow
manag attribut weak
biomed research dont envis dramat shift
growth expect segment especi
recent govern academ spend
expect sinc earlier year still consid
market possess low- mid-single-digit growth
potenti long term even brexit
govern shutdown overal slow growth
concern repres potenti near-term headwind
macroeconom sensit custom group
place review transfer
coverag new analyst expect publish new fair
valu estim second quarter
water end strong note anticip
slight increas fve jan
year solid
perform view may modestli increas
fair valu estim adjust
assumpt revenu adjust earn per share
growth respect fourth quarter
slightli surpass expect even
account much billion share repurchas
manag outlook adjust ep
year exce initi estim thank part
greater oper leverag
post constant-curr growth
improv perform previou quarter
year thank favor condit america
asia meanwhil thermal analysi segment overcam
weak seen third quarter constant
final quarter year
manag said demand europ india remain
challeng think quarter perform
combin stabl underli market condit new
product launch sustain comfort mid-single-digit
growth manag note consist improv
high-resolut mass spec area
weak firm much earli
encourag water constant-curr
revenu growth biopharma market
compani recent lag close peer view
plan slightli boost near-term outlook segment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
